Yaron Werber, an analyst from TD Cowen, maintained the Buy rating on Argenx Se. The associated price target was raised to $1,146.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yaron Werber has given his Buy rating due to a combination of factors including Argenx Se’s strong financial performance and promising future prospects. The company reported a significant increase in Vyvgart sales, surpassing expectations with a robust year-over-year and quarter-over-quarter growth. This growth is largely driven by the successful global launch of the pre-filled syringe formulation, which has been well-received in major markets.
Moreover, Argenx Se’s pipeline remains strong with multiple Phase 3 catalysts expected by the end of 2026, alongside the initiation of a new Phase 2 study in early 2026. Werber also highlights the company’s solid management and financial leverage, which are expected to drive further earnings per share growth. The analyst has raised revenue and earnings estimates, reflecting confidence in the company’s continued market expansion and product uptake.
Werber covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, BioNTech SE, and Roivant Sciences. According to TipRanks, Werber has an average return of 19.7% and a 60.13% success rate on recommended stocks.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $880.00 price target.